Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells by Zhang, Shumin et al.
RESEARCH Open Access
Vascular endothelial growth factor regulates
myeloid cell leukemia-1 expression through
neuropilin-1-dependent activation of c-MET
signaling in human prostate cancer cells
Shumin Zhang
1, Haiyen E Zhau
2, Adeboye O Osunkoya
1,3, Shareen Iqbal
1, Xiaojian Yang
2,4, Songqing Fan
5,
Zhengjia Chen
6, Ruoxiang Wang
1, Fray F Marshall
1, Leland WK Chung
2, Daqing Wu
1*
Abstract
Background: Myeloid cell leukemia-1 (Mcl-1) is a member of the Bcl-2 family, which inhibits cell apoptosis by
sequestering pro-apoptotic proteins Bim and Bid. Mcl-1 overexpression has been associated with progression in
leukemia and some solid tumors including prostate cancer (PCa). However, the regulatory mechanism for Mcl-1
expression in PCa cells remains elusive.
Results: Immunohistochemical analyses revealed that Mcl-1 expression was elevated in PCa specimens with high
Gleason grades and further significantly increased in bone metastasis, suggesting a pivotal role of Mcl-1 in PCa
metastasis. We further found that vascular endothelial growth factor (VEGF) is a novel regulator of Mcl-1 expression
in PCa cells. Inhibition of endogenous Mcl-1 induced apoptosis, indicating that Mcl-1 is an important survival factor
in PCa cells. Neuropilin-1 (NRP1), the “co-receptor” for VEGF165 isoform, was found to be highly expressed in PCa
cells, and indispensible in the regulation of Mcl-1. Intriguingly, VEGF165 promoted physical interaction between
NRP1 and hepatocyte growth factor (HGF) receptor c-MET, and facilitated c-MET phosphorylation via a NRP1-
dependent mechanism. VEGF165 induction of Mcl-1 may involve rapid activation of Src kinases and signal
transducers and activators of transcription 3 (Stat3). Importantly, NRP1 overexpression and c-MET activation were
positively associated with progression and bone metastasis in human PCa specimens and xenograft tissues.
Conclusions: This study demonstrated that Mcl-1 overexpression is associated with PCa bone metastasis.
Activation of VEGF165-NRP1-c-MET signaling could confer PCa cells survival advantages by up-regulating Mcl-1,
contributing to PCa progression.
Background
Acquisition of apoptosis resistance is characteristic of
invasive tumor cells. Elevated expression of anti-apopto-
tic proteins is associated with tumor progression clini-
cally and experimentally [1]. Myeloid cell leukemia-1
(Mcl-1), a member of the Bcl-2 family, sequesters pro-
apoptotic proteins Bim and Bid, thereby inhibiting mito-
chondrial outer membrane permeabilization, a central
control point of apoptosis [2,3]. Mcl-1 overexpression is
associated with progression in leukemia [4] and some
solid tumors including prostate cancer (PCa) [5-7]. Mcl-1
was elevated in primary PCa with high Gleason grades
and metastatic tumors compared to that in prostatic
intraepithelial neoplasia (PIN) or lower grade tumors,
suggesting a pivotal role of Mcl-1 in PCa progression [5].
Angiogenesis favors tumor cell survival, thereby con-
tributing to progression [1]. Vascular endothelial growth
factor (VEGF) is a critical pro-angiogenic factor that
induces proliferation and migration of endothelial cells
within tumor vasculature [8]. VEGF is expressed as sev-
eral alternately spliced isoforms. VEGF165 is pre domi-
nant, with optimal bioavailability, and responsible for
VEGF biological potency, whereas VEGF121 is less
potent but freely diffusible. VEGF binds two highly-
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R2 [8]. Neuropilin-1 (NRP1) was originally identified as
a receptor for the semaphorin 3 subfamily mediating
neuronal guidance and axonal growth [9]. It was subse-
quently found to specifically bind VEGF165 but not
VEGF121 on endothelial cells and tumor cells [9,10].
NRP1 lacks a typical kinase domain, primarily function-
ing as a “co-receptor” to form ligand-specific receptor
complexes. In response to VEGF165, NRP1 couples with
VEGF-Rs to signal in endothelial cells. Though VEGF-
R1 and VEGF-R2 are usually absent or expressed at very
low levels in PCa cells [11], aberrant upregulation of
NRP1 has been frequently observed in high grade and
metastatic PCa and other solid tumors [9,12-16]. Ectopic
expression of NRP1 in PCa cells induced cell migration,
increased tumor size and microvessel density, and inhib-
ited apoptosis [17]. These observations suggested that
N R P 1m a yb ec r i t i c a lf o rP C ap r o g r e s s i o n .N o n e t h e l e s s ,
the mechanism by which NRP1 transmits VEGF signal-
ing in PCa cells lacking VEGF-Rs remains unclear.
Previously we reported that serum VEGF levels corre-
late to bone metastatic status in PCa patients, and acti-
vation of VEGF signaling in PCa cells is associated with
invasive phenotypes in experimental models [18]. In this
study, we correlate Mcl-1 overexpression to PCa pro-
gression towards bone metastasis, and provide evidence
that VEGF regulates Mcl-1 expression through NRP1-
dependent activation of c-MET in PCa cells.
Results
Elevated Mcl-1 expression is associated with PCa progress
and bone metastasis
To investigate the clinical significance of Mcl-1 in PCa
progression, immunohistochemical (IHC) analyses were
performed to determine the expression of Mcl-1 in a
human PCa tissue microarray with matched normal
adjacent tissue and bone metastatic bone specimens
(Figure 1a). We defined tumors with Gleason score 2-6
as well-differentiated (n = 2), Gleason score 7 as inter-
mediately-differentiated (n = 26) and Gleason score 8-10
as poorly-differentiated (n = 43). Mcl-1 immunointensity
was increased from normal tissues to well-differentiated
cancer and further elevated in high grade PCa, although
the difference between Mcl-1 intensity in intermediate-
and poorly-differentiated cancers was not statistically
significant (p = 0.93). Intriguingly, Mcl-1 staining in
bone metastatic tumors (n = 6) was remarkably
increased compared to that in either intermediate- or
poorly-differentiated PCa (p < 0.002). These data corre-
lated elevated Mcl-1 expression to clinical PCa progres-
sion, particularly bone metastasis.
Mcl-1 is a survival factor in human PCa cells
We have established several lines of human PCa models
that closely mimic the clinical progression of PCa bone
metastasis, including the ARCaP model [19,20]. When
inoculated either orthotopically or intracardially,
ARCaPM cells are capable of metastasizing sponta-
neously to bone and soft tissues, forming mixed osteo-
blastic and osteolytic lesions in mouse skeleton
[19,21,22]. The ARCaPM-C2 subclone, derived from
metastatic bone tissues after two rounds of intracardiac
injection of ARCaPM cells in athymic mice, forms pre-
dictable metastases to bone, adrenal gland and other
soft tissue with higher propensity and shorter latency
[21,22] (Figure 1b). Reverse transcription-PCR (RT-PCR)
and immunoblotting analyses found that Mcl-1 was sub-
stantially expressed by ARCaPM cells, and further
increased in ARCaPM-C2 cells (Figure 1c). Similarly,
increased Mcl-1 expression was observed in metastatic
C4-2 and C4-2B cells [23] when compared to their par-
ental, androgen-dependent human PCa cell line LNCaP
(Additional file 1, Figure S1a). These results suggested a
possible association between Mcl-1 expression and inva-
sive phenotypes of PCa cells.
To examine the function of Mcl-1 in PCa cell survival,
a Mcl-1 small-interfering RNA (siRNA) was transfected
into ARCaPM cells. siRNA treatme nt effectively inhib-
ited Mcl-1 expression and significantly reduced ARCaPM
cell viability by ~36% after 72 h (Figure 1d). Annexin V
staining by fluorescence-activated cell sorting (FACS)
analysis showed that the Mcl-1 siRNA induced apopto-
sis in 24.4-2.3% of ARCaPM cells (Figure 1e). These
results indicated that Mcl-1 may be an important survi-
val factor in PCa cells.
VEGF regulates Mcl-1 expression in human PCa cells
Previously we reported that ARCaPM cells express high
levels of endogenous VEGF, regulated by a cyclic AMP-
response element binding protein (CREB)-hypoxia-indu-
cible factor (HIF)-dependent mechanism in normoxic
conditions [18]. In the present study, RT-PCR assay that
could differentiate mRNA expression of VEGF165 and
VEGF121 isoforms [18] was performed in ARCaPM and
ARCaPM-C2 cells, showing a significant increase in the
expression of both VEGF isoforms in ARCaPM-C2 cells,
a sc o n f i r m e da tp r o t e i nl e vel by enzyme-linked immu-
nosorbent assay (ELISA) (Figure 2a). Similarly, C4-2
cells express higher levels of VEGF when compared to
LNCaP cells (Additional file 1, Figure S1b). These data
suggested that VEGF expression is elevated in metastatic
PCa cells.
VEGF potently stimulates endothelial cell proliferation
and migration, an underlying mechanism for angiogen-
esis during tumor progression. However, neither exo-
genous human VEGF165 (Figure 2b) nor VEGF121
(Additional file 1, Figure S1c) significantly affected the
proliferation of ARCaPM cells at a non-saturating range
(5-100 ng/ml), suggesting that VEGF is not a potent
mitogen in PCa cells. Intriguingly, VEGF165 was found
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and time-dependent manner, with the maximum accu-
mulation of Mcl-1 mRNA after 2 h-incubation at the
concentration of 10 ng/ml. Western blot analysis con-
firmed a remarkable increase of Mcl-1 protein in
ARCaPM cells (Figure 2c) and LNCaP cells (Additional
file 1, Figure S1d) treated with VEGF165. Conversely,
when ARCaPM cells were transfected with a VEGF
siRNA nucleotide that selectively inhibited expression of
VEGF165 but not VEGF121, expression of Mcl-1, but not
Bcl-2, was reduced after 72 h (Figure 2d). Notably, Mcl-
1 expression was not affected by VEGF121 treatment
(Additional file 1, Figure S1e). These results indicated
that VEGF165 may specifically regulate Mcl-1 expression
in PCa cells.
Differential expression of VEGF-Rs in PCa cells
Expression of VEGF-Rs was examined in several PCa
cell lines with human umbilical vein endothelial cells
(HUVEC) as a positive control (Figure 3a, and Addi-
tional file 1, Figure S1f). VEGF-R1 was undetectable in
Figure 1 Mcl-1 is a survival factor in human PCa cells. (a) IHC staining of Mcl-1 in human PCa tissue microarray consisting of normal
adjacent tissues, primary PCa and bone metastases. (b) Intracardiac (i.c) injection of ARCaPM cells in athymic mice resulted in metastases to bone
and soft tissues. The ARCaPM-C2 subclone was derived from metastatic bone tissues after two rounds of intracardiac inoculation of ARCaPM cells.
(c) Endogenous Mcl-1 expression in the ARCaPM model was examined by RT-PCR and western blotting analyses. (d) Effect of Mcl-1 siRNA on
ARCaPM cell viability. Subconfluent ARCaPM cells on a 6-well plate were transiently transfected with Mcl-1 siRNA (30 nM) for 72 h. Endogenous
expression of Mcl-1 at the mRNA and protein levels, and cell viability of ARCaPM cells as counted with trypan blue staining, were significantly
inhibited by Mcl-1 siRNA treatment compared to the control. (e) Effects of Mcl-1 siRNA on ARCaPM cell apoptosis. Subconfluent ARCaPM cells
were transfected with Mcl-1 siRNA or control siRNA for 72 h, expression of annexin V was measured by FACS.
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be observed in ARCaPM-C2 cells. However, NRP1 was
ubiquitously expressed in PCa cells at a level compar-
able to that in HUVEC, and higher in metastatic
ARCaPM-C2, PC3, C4-2 and C4-2B cells. NRP2, the
“co-receptor” for VEGF-C [8], was not detected in PCa
cells. These data implied that NRP1 may be the major
receptor mediating VEGF effects in PCa cells.
NRP1 regulates both basal expression and VEGF
induction of Mcl-1 in PCa cells
The role of NRP1 in the regulation of Mcl-1 expression
was investigated. ARCaPM cells cultured in serum-con-
taining T-medium were transiently transfected with a
NRP1 expression vector. Compared to the control, ecto-
pic expression of NRP1 resulted in increased Mcl-1 at
both the mRNA and protein levels (Figure 3b). Conver-
sely, transfection with a NRP1 siRNA specifically inhib-
ited NRP1 and reduced endogenous Mcl-1 expression in
ARCaPM cells (Figure 3c). These data indicated that
NRP1 may be required and sufficient for basal expres-
sion of Mcl-1 in PCa cells. Further, ARCaPM cells were
transfected with NRP1 siRNA or control siRNA, and
incubated with VEGF165 in serum-free T-medium for
indicated time. Figure 3d showed that expression of
NRP1 siRNA, but not control siRNA, abrogated
VEGF165 induction of Mcl-1 in ARCaPM cells. These
data indicated an indispensible role of NRP1 in mediat-
ing VEGF165 induction of Mcl-1 in PCa cells.
c-MET signaling is required for VEGF regulation of Mcl-1
in PCa cells
Since NRP1 does not contain typical kinase receptor
sequences [24], we hypothesized that NRP1 may interact
with certain tyrosine kinase receptor(s) to transmit VEGF
autocrine signal in PCa cells lacking VEGF-Rs. Two recent
studies independently demonstrated that NRP1 physically
binds c-MET, and potentiates c-MET activation in
Figure 2 VEGF165 regulates Mcl-1 expression in PCa cells. (a) VEGF expression in ARCaPM and ARCaPM-C2 cells, as determined by RT-PCR and
ELISA (conditioned medium). (b) Effects of recombinant VEGF165 on cell proliferation as determined by MTS assay. Top, ARCaPM cells were
seeded in 96-well plates (1 × 10
3cells/well) for 24 h, and serum-starved overnight. The cells were further incubated with varying concentrations
of VEGF165 in serum-free T-medium for 72 h. Bottom, ARCaPM cells were incubated with PBS or VEGF165 (50 ng/ml) in serum-free T-medium for
varying times. (c) VEGF165 effects on Mcl-1 expression. ARCaPM cells were treated with VEGF165 at indicated concentrations and times, and Mcl-1
mRNA expression was measured. For immunoblotting, ARCaPM cells were incubated with VEGF165 (10 ng/ml) for 72 h. (d) Effects of VEGF siRNA
on Mcl-1 expression. ARCaPM cells were transfected with VEGF siRNA or control siRNA (80 nM) for 72 h.
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creatic cancer cells [25,26]. It is therefore plausible that c-
MET may be involved in VEGF regulation of Mcl-1 in
PCa cells. Indeed, HGF activation of c-MET signaling has
been shown to transcriptionally increase Mcl-1 expression
in primary human hepatocytes [27].
A c-MET siRNA construct was transfected into
ARCaPM cells, which effectively inhibited endogenous c-
MET (Figure 4a). c-MET siRNA treatment reduced
Mcl-1 protein expression, suggesting that c-MET is
involved in maintaining basal expression of Mcl-1 in
PCa cells. Interestingly, however, recombinant HGF
t r e a t m e n td i dn o ts i g n i f i c a ntly affect Mcl-1 expression
at either RNA or protein levels (Figure 4b), indicating
that HGF-dependent activation of c-MET signaling is
not sufficient to induce Mcl-1 expression in these cells.
Figure 3 NRP1 is required for basal expression and VEGF165 induction of Mcl-1 in ARCaPM cells. (a) Expression of VEGF-Rs in PCa cells and
HUVEC. (b) Effect of ectopic expression of NRP1 on Mcl-1 basal level. Subconfluent ARCaPM cells on 6-well plates were transfected with pCMV-
NRP1 or pCMV-XL4 (16 μg) for 48 h (for RT-PCR) or 72 h (for immunoblotting). (c) Effects of NRP1 siRNA on Mcl-1 basal expression. ARCaPM cells
were transfected with NRP1 siRNA or control siRNA (60 nM) for 48 h (for RT-PCR) or 72 h (for immunoblotting). (d) Effects of NRP1 siRNA on
VEGF165 induction of Mcl-1. ARCaPM cells were transfected with NRP1 siRNA or control siRNA for 48 h, respectively. Cells were then serum-
starved overnight, and treated with VEGF165 (10 ng/ml) or PBS for 2 h.
Figure 4 c-MET signaling is required for VEGF165 induction of Mcl-1 in ARCaPM cells. (a) Effects of c-MET inhibition on Mcl-1 expression.
ARCaPM cells were transfected with c-MET siRNA or control siRNA (30 nM) for 72 h. (b) Effects of recombinant HGF treatment (10 ng/ml) on
Mcl-1 expression at RNA (0, 2, 4 and 6 h) and protein levels (72 h). (c) ARCaPM cells were transfected with c-MET siRNA or control siRNA for 48 h,
serum-starved overnight, and treated with VEGF165 (10 ng/ml) for 2 h. (d) ARCaPM cells were treated with PHA-665752 (0.5 μM) or dimethyl
sulfoxide (DMSO) for 2 h, before treatment with VEGF165 (10 ng/ml) or PBS for 2 h.
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required for VEGF165 induction of Mcl-1. Indeed,
VEGF165 only induced Mcl-1 expression in ARCaPM cells
transfected with control siRNA, not in those expressing
c-MET siRNA (Figure 4c). PHA-665752, a c-MET selec-
tive inhibitor [28], was used to treat ARCaPM cells prior
to addition of VEGF165. PHA-665752 significantly attenu-
ated VEGF165 induction of Mcl-1 in ARCaPM cells (Fig-
ure 4d). These data indicated that c-MET signaling is
required for VEGF regulation of Mcl-1 in PCa cells.
VEGF induces c-MET activation by a NRP1-dependent
mechanism in PCa cells
c-MET activation involves phosphorylation of several tyro-
sine residues including those at positions 1230, 1234, and
1235 [29]. To assess whether VEGF165 could induce c-
MET activation, and whether this process was mediated
by NRP1, ARCaPM cells were transiently transfected with
NRP1 siRNA or control siRNA before VEGF165 treatment.
VEGF165 induced rapid phosphorylation of c-MET at
Tyr1230/1234/1235 residues in ARCaPM cells transfected
with control siRNA, but this effect was significantly atte-
nuated by expression of NRP1 siRNA. Expression of total
c-MET protein was not affected by siRNA treatment (Fig-
ure 5a). These data indicated that VEGF165 activated c-
MET signaling independent of HGF, and NRP1 may be
indispensible in this process.
VEGF promotes interaction between NRP1 and c-MET in
PCa cells
To explore whether VEGF could induce physical inter-
action between NRP1 and c-MET, an immunoprecipita-
tion assay was performed in ARCaPM cells treated with
VEGF165 for varying times. First, endogenous NRP1 pro-
tein was immunoprecipitated (Figure 5b, upper). There
was a constitutive association between c-MET and
NRP1 in the absence of VEGF165.U p o nV E G F 165 treat-
ment, presence of c-MET in the NRP1 immunoprecipi-
tates increased at 30 min and returned to baseline at 60
min. Phosphorylated c-MET (p-c-MET) significantly
increased at 15 min following VEGF165 treatment,
reached a peak at 30 min and slightly decreased in 60
min. Reciprocal immunoprecipitation with anti-c-MET
antibody confirmed an association of NRP1 with c-MET
in the absence of VEGF165. The presence of NRP1 and
p-c-MET in the protein complex exhibited a similar
time course following VEGF165 stimulation, with the
peak at 30 min (Figure 5b, low).
Confocal microscopy was performed to determine
whether VEGF165 promotes NRP1 interaction with c-MET
Figure 5 VEGF165 induces c-MET activation through a NRP1-dependent mechanism. (a) Effects of NRP1 depletion on VEGF165-mediated c-
MET phosphorylation. ARCaPM cells were transfected with NRP1 siRNA or control siRNA for 48 h, serum-starved overnight, then treated with
VEGF165 (10 ng/ml) for 60 min. (b) Immunoprecipitation assay of NRP1-c-MET interaction. Serum-starved ARCaPM cells were treated with VEGF165
(10 ng/ml) for the indicated times, and immunoprecipitated with anti-NRP1 (upper), or anti-c-MET (low) antibody. (c) Co-localization of NRP1 and
c-MET or p-c-MET. Serum-starved ARCaPM cells were treated with VEGF165 (10 ng/ml) or PBS for the indicated times. Immunofluorescence
staining of NRP1, c-MET or p-c-MET was performed and visualized by confocal microscopy. Arrows indicate co-localization of NRP1 and c-MET or
p-c-MET.
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MET were found to be constitutively associated on plasma
membrane, with the intensity of co-localization further
increased at 30 min upon VEGF165 treatment (Figure 5c,
left panel). Notably, there was a more significant increase
in the intensity of co-localization of NRP1 and p-c-MET
following VEGF165 stimulation (Figure 5c, right panel).
The data independently supported a mechanism that
NRP1 may be constitutively associated with c-MET on
plasma membrane. Upon VEGF165 binding, NRP1 may
further recruit c-MET and facilitate its activation, subse-
quently transmitting VEGF165 signal (Figure 6).
Role of Src kinases and signal transducers and activators
of transcription 3 (Stat3) in VEGF induction of Mcl-1 in
PCa cells
Activation of the Src kinase-Stat3 pathway is an impor-
tant downstream event in c-MET signaling [30,31] (refer
to Figure 6). Recently, a Stat3 cis-element was identified
in human Mcl-1 promoter [32]. We investigated
whether the Src kinase-Stat3 pathway is a downstream
component in NRP1 signaling in ARCaPM cells (Figure
7a). Indeed, expression of NRP1 siRNA in ARCaPM cells
significantly inhibited phosphorylation of Src kinases at
Tyr416 (p-Src), as well as activation of Stat3 at Tyr705
(p-Stat3), without altering expression of endogenous Src
kinases and Stat3.
Next we examined whether VEGF induces activation
of Src kinase-Stat3 signaling in ARCaPM cells (Figure
7b). VEGF165 rapidly induced expression of both p-Src
(Tyr416) and p-Stat3 (Tyr705) in a time-dependent
manner in ARCaPM cells, with the peak at 60 min. Sig-
nificantly, VEGF165 promoted rapid intracellular translo-
cation of p-Stat3 (Tyr705) from the cytoplasm to the
nucleus, indicating activation of Stat3-dependent gene
expression. By contrast, nuclear presence of p-Stat3
(Ser727), which has been associated with HGF-induced
M c l - 1e x p r e s s i o ni np r i m a r yh u m a nh e p a t o c y t e s[ 2 7 ] ,
was not affected. These data indicated that Src kinase-
Stat3 pathway activation may be an important event fol-
lowing VEGF165 stimulation.
Finally, we assessed the role of Src kinase-Stat3 signal-
ing in VEGF165 regulation of Mcl-1. PP2, a selective
inhibitor of Src kinases [33], was used to treat ARCaPM
cells before VEGF165 stimulation. PP2 treatment effec-
tively abrogated VEGF165 induction of Mcl-1 (Figure
7c). Similarly, Mcl-1 mRNA expression was rapidly
induced by VEGF165 in ARCaPM cells transfected with
control siRNA, but not in the cells expressing Stat3
siRNA (Figure 7d). Collectively these data suggested that
Src kinase-Stat3 signaling may be required for VEGF
induction of Mcl-1 in PCa cells (Figure 6).
NRP1 overexpression and c-MET activation are positively
associated with human PCa progression and bone
metastasis
To validate the clinical significance of NRP1-c-MET sig-
naling in PCa progression, and avoid the potential bias
from using human PCa cell lines, IHC analyses were per-
formed to determine the expression of NRP1 and p-c-
MET in human PCa tissue specimens. Prostatic tissue
specimens of normal/benign glands, primary and bone
metastatic tumors were analyzed. NRP1 expression was
increased from normal/benign glands (0/5) or well-differ-
entiated cancer (1/5) to poorly-differentiated cancers (5/5)
and bone metastatic tissues (5/5) (Figure 8a). NRP1 stain-
ing was also determined in tumor specimens from the
ARCaPM xenograft model in which ARCaPM cells were
inoculated into athymic mice orthotopically, resulting in
skeletal metastases with a short latency [21]. Consistently,
NRP1 expression was significantly greater in bone meta-
static tumors than in primary tumors (Figure 8b).
We and others have reported that c-MET overexpres-
sion is positively associated with PCa progression
[34,35]. As shown in Figure 8c, p-c-MET was expressed
at a low level in normal human prostatic tissue, but
increased significantly from well-differentiated and inter-
mediate to poorly-differentiated primary PCa. Impor-
tantly, bone metastatic PCa specimens displayed a
higher expression of p-c-MET than primary PCa. p-c-
MET expression was also remarkably increased in bone
metastatic ARCaPM tumors (Figure 8d).
Discussion
Aberrant overexpression of Mcl-1 has been associated
with poor prognosis and resistance to chemotherapy in
a variety of human cancers [36]. Sensitizing tumor cells
to apoptosis induction by selectively targeting Mcl-1, in
combination with conventional chemotherapy, has
Figure 6 A proposed model for VEGF165 regulation of Mcl-1 in
PCa cells. NRP1 may be constitutively associated with c-MET on
plasma membrane. VEGF165 engagement recruits c-MET into the
protein complex and promotes its interaction with NRP1, thereby
enhancing phosphorylation of c-MET. Src kinase-Stat3 signaling is
subsequently activated, resulting in nuclear translocation of p-Stat3
and activation of Mcl-1 expression. Increased intracellular Mcl-1
protects PCa cells from apoptosis.
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this study, we presented evidence that elevated Mcl-1
expression is associated with clinical PCa progression,
particularly bone metastasis. We further showed that
activation of VEGF-NRP1-c-MET signaling is responsi-
b l ef o rM c l - 1e x p r e s s i o n ,w h i c hm a yc o n f e rs u r v i v a l
advantages allowing PCa cells to evade apoptosis and
progress towards invasive states (Figure 6).
Only limited information are available on Mcl-1 expres-
s i o np r o f i l ei nP C a .A ne a r l ys t u d yf o u n dt h a tM c l - 1
expression was increased at tumors (81%) compared with
only 38% in PIN. The percentage of Mcl-1-positive cells
was typically higher in Gleason grade 8-10 tumors and
metastasis than lower grade tumors, but there was no sig-
nificant difference in Mcl-1 immunointensity between
high grade tumors (47%) and metastasis in lymph node
(38%) and bone (50) [5]. Our present study confirmed ele-
vated Mcl-1 expression in high grade (≥ 7) PCa, though
the difference between Gleason score 7 and 8-10 tumors is
not statistically significant. Intriguingly, our results
revealed a remarkable increase in Mcl-1 immunointensity
in bone metastasis compared to primary tumors, indicating
that Mcl-1 overexpression is positively correlated to PCa
progression towards metastatic status in clinical situation.
Accumulating evidence suggests that the function of
VEGF in tumor progression may not be limited to
angiogenesis [38]. Numerous tumor cells express signifi-
cant levels of VEGF-Rs, which could engage VEGF and
initiate multiple signaling responses involved in cell pro-
liferation, survival and migration. VEGF autocrine sig-
naling confers a degree of self-sufficiency that may be
crucial to metastasis as the microenvironment becomes
increasingly hostile. Nonetheless, it remains controver-
sial whether VEGF has significant autocrine effects in
PCa cells, since the “classical” VEGF-Rs, i.e., VEGF-R1
and -R2, are undetectable in most established PCa cell
lines [11,39,40]. Previously we reported that serum
VEGF is positively associated with bone metastatic sta-
tus in PCa patients, and recapitulated this close associa-
tion in the ARCaP model [18]. In this study, we
investigated whether VEGF could affect PCa cell beha-
vior in an autocrine manner. Intriguingly, VEGF165 was
found to be capable of inducing Mcl-1 expression within
a non-saturating range, suggesting it may act as a survi-
val factor in PCa cells. Moreover, NRP1 was found to be
highly expressed by PCa cell lines and displayed a posi-
tive association with invasiveness, suggesting that it may
be the primary receptor responsible for VEGF autocrine
Figure 7 Src kinase-Stat3 signaling mediates VEGF165 induction of Mcl-1 expression in ARCaPM cells. (a) Effects of NRP1 inhibition on
phosphorylation of Src kinases and Stat3. ARCaPM cells were transfected with NRP1 siRNA or control siRNA for 72 h. (b) Effects of VEGF165 on the
phosphorylation of Src kinases and Stat3. ARCaPM cells were treated with VEGF165 (10 ng/ml) for the indicated time, and immunoblotting was
performed on total lysates (left) and nuclear extracts and cytoplasmic proteins (right). (c) Effects of Src kinases on VEGF165 regulation of Mcl-1.
ARCaPM cells were treated with PP2 (10 μM) or DMSO for 2 h before treatment with VEGF165 or PBS. (d) Effects of Stat3 depletion on VEGF165
induction of Mcl-1. ARCaPM cells were transfected with Stat3 siRNA or control siRNA (80 nM) for 48 h, serum-starved overnight, then treated with
VEGF165 (10 ng/ml) or PBS for 2 h.
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ported an indispensible role of NRP1 in mediating
VEGF165 regulation of Mcl-1 in metastatic PCa cells.
Importantly, a positive association between NRP1
expression and in vivo bone metastatic potential was
found in ARCaPM xenografts and further confirmed in
clinical PCa specimens. These data collectively support a
novel role of NRP1 in PCa progression and metastasis,
presumably by transmitting the VEGF autocrine survival
signal and enabling PCa cells to evade apoptosis.
NRP1 is not a typical “signaling receptor” since it lacks
sequences predicted to have kinase receptor activities
[24]. Direct interaction between NRP1 and VEGF-Rs or
plexin A is essential to its function in prioritizing differ-
ential signals from VEGF165 or semaphorin 3 in endothe-
lial cells and nerve cells [24]. Recent studies found that
Figure 8 Expression of NRP1 and p-c-MET is associated with bone metastatic status of human PCa specimens and the ARCaPM model.
IHC analyses of NRP1 expression in human normal/benign, cancerous and metastatic prostatic tissue specimens (a) and primary and bone
metastatic tissue specimens from ARCaPM model (b), and of p-c-MET expression in human PCa progression (c) and ARCaPM xenografts (d).
Arrows indicate positively-stained cells.
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three amino acids (SEA-COOH), may be required for the
interaction between NRP1 and its binding partners,
including NRP1-interacting protein (NIP; or RGS-GAIP-
interacting protein, GIPC) and VEGF-R2 [41,42]. How-
ever, the molecular effects and mechanism for NRP1-
mediated signaling in tumor cells, especially in the
absence of VEGF-Rs, remain elusive. It has been pro-
posed that NRP1 may store or sequester VEGF165 and
attract endothelial cells towards tumor, contributing to
angiogenesis via juxtacrine or paracrine mechanisms
[9,17]. In this study, we investigated whether NRP1 is
required for VEGF165 autocrine signaling in PCa cells
lacking VEGF-Rs. We presented evidence that NRP1 and
c-MET are physically associated on plasma membrane,
and in response to VEGF165 stimulation, their interaction
may significantly facilitate further recruitment and activa-
tion of c-MET. Though the structural and molecular
basis for interaction between the two receptors needs to
be further investigated, this study indicates for the first
time that c-MET activity can be modulated by VEGF,
and the NRP1-c-MET interaction may be a critical com-
ponent in transmitting the VEGF survival signal in PCa
cells. It may be plausible to assign c-MET phosphoryla-
tion as an indicator for activation of NRP1 autocrine sig-
naling in tumor cells. Using human PCa tissue specimens
as the “gold standard”, we observed that NRP1 and p-c-
MET were both significantly increased with progression
of primary PCa, and further elevated in bone metastatic
PCa, suggesting that activation of NRP1-c-MET signaling
may be positively associated with clinical PCa progres-
sion. It is worth noting that these results need cautious
interpretation since a limited number of patient speci-
mens was examined, and the polyclonal antibody against
p-c-MET has not been fully validated for immunohisto-
chemical analysis in tissue sections.
In human primary hepatocytes, HGF transcriptionally
induced Mcl-1 expression, but not Bcl-2 or Bcl-x(L)
[27]. Our studies found that, however, HGF treatment
did not significantly affect Mcl-1 protein expression in
ARCaPM cells, suggesting HGF activation of c-MET sig-
naling may not be sufficient to increase Mcl-1 expres-
sion. We postulated that VEGF165 may utilize a different
mechanism to regulate Mcl-1 expression in PCa cells.
An important observation supporting this hypothesis is
that VEGF165 only rapidly induced Stat3 phosphoryla-
tion at Tyr705, but not altering Ser727 phosphorylation
in ARCaPM cells. In hepatocytes, however, HGF trig-
gered Ser727, but not Tyr705, phosphorylation of Stat3
[27]. It will be intriguing to investigate the role of
NRP1-c-MET interaction in differentiating extracellular
ligands, i.e., VEGF165 or HGF, and activating distinct
downstream cascades leading to Mcl-1 expression in a
highly cell context-dependent fashion.
Mcl-1 is a protein with very short half-life and is
highly regulated at multiple levels in response to survival
and differentiation signals. Rapid turnover of Mcl-1 pro-
tein can be initiated by stress (such as serum withdra-
wal) through caspase-mediated and proteasome-
dependent degradation in tumor cells [3]. Previous
study found that VEGF protects multiple myeloma cells
against apoptosis by up-regulating Mcl-1 protein in a
time-dependent manner, peaking at 6 h and returning
to baseline after 24 h; change in Mcl-1 mRNA expres-
sion was not reported [43]. In ARCaPM cells, however,
VEGF165 treatment rapidly induced Mcl-1 mRNA
expression and significantly increased Mcl-1 protein
level at 72 h. Though whether VEGF165 may also regu-
late Mcl-1 expression at other levels needs to be further
investigated, the data presented here suggest that tran-
scriptional activation, presumably mediated by Stat3, is
an important mechanism for VEGF165 induction of Mcl-
1 in PCa cells.
Interrupting NRP1 functions with mimetic peptides
and monoclonal antibodies is being developed in xeno-
graft models of human cancers [44,45]. NRP1 monoclo-
nal antibody has been shown to effectively inhibit tumor
vascular remodeling, rendering vessels more susceptible
to anti-VEGF therapy [45]. If the VEGF165-NRP1-c-
MET pathway is required for Mcl-1 expression and sur-
vival in PCa cells, it would be intriguing to evaluate
whether targeting NRP1 couldi n t e r r u p tb o t hN R P 1 - c -
MET signaling in tumor cells (survival) and NRP1-
VEGF-Rs signaling in endothelial cells (angiogenesis).
Inhibition of NRP1 signaling may be a promising strat-
egy alone or in combination with other therapeutic
approaches for treating PCa.
Methods
Cell culture
Human PCa cell lines ARCaPM,A R C a P M-C2, PC3,
LNCaP, C4-2 and C4-2B, were routinely maintained in
T-medium (Invitrogen, Carlsbad, CA) with 5% fetal
bovine serum (FBS). ARCaPM-C2 subclone was derived
from ARCaPM bone metastatic tissues as described pre-
viously [21,22]. Where specified, ARCaPM cells were
serum-starved overnight, and treated with recombinant
human VEGF165,V E G F 121, HGF (R&D Systems, Min-
neapolis, MN), c-MET inhibitor PHA-665752 (Calbio-
chem, San Diego, CA), or Src kinase inhibitor (PP2)
(Calbiochem) in serum-free T-medium. HUVEC (The
American Type Culture Collection, Manassas, VA) were
maintained in endothelial basal growth medium (EBM-
2) with 2% FBS. Cell proliferation was measured using
the CellTiter 96 AQ proliferation assay according to the
manufacturer’s instructions (Promega, Madison, WI).
Viable cells were counted in triplicate using a hemacyt-
ometer and trypan blue staining.
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IHC staining of NRP1 and p-c-MET on human normal/
benign prostatic glands, well- and poorly-differentiated
primary PCa and bone metastatic PCa tissue specimens
was performed as described previously [18] using goat
anti-NRP1 antibody (C-19, Santa Cruz Biotechnology,
Santa Cruz, CA; 1:100) and rabbit anti-p-c-MET
(Tyr1230/1234/1235) antibody (44888G, Invitrogen;
1:100). IHC analysis of Mcl-1 expression was performed
on a human PCa progression tissue microarray speci-
men (US BioMax, Inc., Rockville, MD) using rabbit anti-
Mcl-1 antibody (S-19, Santa Cruz Biotechnology, 1:150).
Matching normal serum was used as negative control.
All IHC common reagents were obtained from Dako
(Carpinteria, CA). Positive expression of NRP1, p-c-
MET and Mcl-1 was defined as >15% positive staining
in cell population.
Transfection
The vector harboring NRP1 cDNA (pCMV-NRP1) and
the control (pCMV-XL4) (Origene, Rockville, MD) were
transfected into ARCaPM cells for 48-72 h using lipofec-
tamine 2000 (Invitrogen). Small interfering RNA
(siRNA) nucleotides were transfected into ARCaPM cells
according to the manufacturer’si n s t r u c t i o n s .V E G F
siRNA, Mcl-1 siRNA, Stat3 siRNA and control siRNA-A
were purchased from Santa Cruz Biotechnology. NRP1
silencer® select validated siRNA and silencer® select con-
trol siRNA
#1 were obtained from Ambion, Inc., (Austin,
TX). c-MET ON-TARGET plus siRNA and ON-TAR-
GET plus siRNA control were purchased from Dharma-
con, Inc, (Chicago, IL).
Western blot analysis
Total cell lysates were prepared using radioimmunopre-
cipitation (RIPA) buffer (Santa Cruz Biotechnology).
Nuclear proteins were extracted using a Novagen kit
(EMD Biosciences, San Diego, CA). Immunoblotting
analysis followed standard procedure [18] with anti-
Stat3, anti-p-Stat3 (Ser705), anti-Src and anti-p-Src
( T y r 4 1 6 )( C e l lS i g n a l i n g ,D a n v e r s ,M A ) ;a n t i - p - S t a t 3
(Tyr705) (Upstate, Charlottesville, VA); anti-Mcl-1, anti-
NRP1 (C-19), anti-NRP2, anti-VEGF-R2, and anti-c-
MET (Santa Cruz Biotechnology); anti-p-c-MET
(Tyr1230/1234/1235) (Invitrogen); and anti-b-actin
(Sigma, St. Louis, MO).
RT-PCR
Total RNA was prepared with Qiagen RNeasy Kit
(Valencia, CA), and RT-PCR was performed using the
SuperScriptIII® One-Step RT-PCR kit (Invitrogen) fol-
lowing the manufacturer’s protocol. The specific primer
pairs are: 5’-GAGGAGGAGGAGGACGAGTT-3’ (for-
ward) and 5’-GTCCCGTTTTGTCCTTACGA-3’
(reverse) (for Mcl-1); 5’-AGGACAGAGACTGCAAG
TATGAC-3’ (forward) and 5’-AACATTCAGGACCT
CTCTTGA-3’ (reverse) (for NRP1). The primers for
VEGF, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) [18] and Stat3 [46] were described previously.
The primer pairs for human VEGF-R1, VEGF-R2 and
NRP2 were purchased from R&D Systems.
ELISA
Subconfluent PCa cells were cultured in serum-free T-
medium for 72 h before conditioned medium was col-
lected. VEGF concentrations were analyzed using a
Quantikine ELISA kit (R&D Systems) and normalized
with total protein concentrations in CM.
Immunofluorescence and confocal imaging
Immunofluorescence was performed as described pre-
viously [47]. Goat anti-NRP1 antibody (C-19), rabbit
anti-c-MET antibody (C-12, Santa Cruz Biotechnology),
or rabbit anti-p-c-MET (Tyr1230/1234/1235) antibody
was incubated with subconfluent ARCaPM cells at 4°C
overnight. Either anti-goat Alexa Fluor® 546 or anti-rab-
bit Alexa Fluor® 488 secondary antibody (Invitrogen)
was used at a dilution of 1:500. Cells were imaged on a
Zeiss LSM 510 META [47]. In all cases, either a 63× or
100× Zeiss Plan-Apo oil objective was used (numerical
aperture of 1.3 and 1.4, respectively). All images had
contrast expansion performed in Adobe Photoshop.
Immunoprecipitation
The Immunoprecipitation Starter Pack (GE healthcare
Bio-Sciences Corp., Piscataway, NJ) was used according
to the manufacturer’s instructions. Total lysates (1 mg)
were immunoprecipitated with rabbit anti-c-MET anti-
body (C-12), rabbit anti-NRP1 antibody (H-286, Santa
Cruz Biotechnology), or normal rabbit IgG (R&D Sys-
tems). Protein A/G Sepharose 4 Fast Flow beads were
added to precipitate proteins, then washed and eluted.
The samples were further processed for western blot
analysis.
Apoptosis analysis
Cells were stained with an Annexin V-PE apoptosis
detection kit (BD Biosciences, San Jose, CA) following
the manufacturer’s protocol, and measured using a
fluorescence-activated cell sorting (FACS) caliber bench-
top flow cytometer (Becton Dickinson, Franklin Lakes,
NJ). The data were analyzed using FlowJo software
(Tree Star, Inc., Ashland, OR).
Data analysis
Significance levels for comparisons of Mcl-1 expression
in different Gleason score PCa were calculated by using
the 2-sample t test. Treatment effects were evaluated
using a two-sided Student’s t test. All data represent
three or more experiments. Errors are S.E. values of
averaged results, and values of p < 0.05 were taken as a
significant difference between means.
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Page 11 of 13Additional file 1: Figure S1. (a) Endogenous Mcl-1 expression in the
lineage-related LNCaP, C4-2 and C4-2B cells, as determined by RT-PCR
and western blotting analyses. (b) ELISA of VEGF levels in conditioned
media of LNCaP and C4-2 cells, shown as relative VEGF concentrations
normalized by total protein concentrations of the CM. (c) Effects of
recombinant VEGF121 on the proliferation of ARCaPM cells. 1 × 10
3cells
were seeded in 96-well plates for 24 h, serum-starved overnight, and
cultured in the absence or presence of varying concentrations of
rVEGF121 for 72 h. MTS assay was then performed. (d) Effects of VEGF165
on Mcl-1 expression in LNCaP cells. Subconfluent LNCaP cells were
serum-starved overnight, and incubated for 72 h in the presence of
VEGF165 (10 ng/ml) or PBS. Western blotting was performed. (e) Effects of
VEGF121 on Mcl-1 expression in ARCaPM cells. Subconfluent ARCaPM cells
were serum-starved overnight, and incubated for 72 h in the presence of
VEGF121 (10 ng/ml) or PBS. Western blotting was performed. (f)
Expression of endogenous NRP1 in LNCaP, C4-2 and C4-2B cells, as
determined by RT-PCR and western blotting analyses. (g) Nuclear
expression of c-MET and p-c-MET in ARCaPM and ARCaPM-C2 cells. TATA
binding protein (TBP) was used as internal control of nuclear proteins.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-4598-9-9-
S1.TIFF]
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